AstraZeneca secures two new deals with US government: Report

AstraZeneca, British drugmaker that is working on a vaccine in collaboration with Oxford University on June 9 said that it has secured a fresh deal with authorities in United States to vance antibody-related coronavirus treatments. company did t reveal any details about deal, however, media reports suggest that it has signed agreements with Biomedical vanced Research and Development Authority (BARDA) and Defense vanced Research Projects ncy (DARPA). new deals will see AstraZeneca moving its two COVID-19 antibody rapies into clinal studies in next two months. 

Re: Coronavirus Update: AstraZeneca Drug Company Acquires Orders For COVID-19 Vaccine

AstraZeneca last week signed new agreements with companies to double its production from one billion doses to two billion doses. British company signed deals with Coalition for Epidemic Preparedness Invations (CEPI), Gavi Vaccine Alliance, and Serum Institute of India (SII), world's largest manufacturer of vaccines by volume, to bring vaccine to low- and middle-income countries and beyond.

Re: AstraZeneca Secures Orders For COVID-19 Vaccine

COVID-19 vaccine

Oxford University’s Jenner Institute, working with Oxford Vaccine Group has developed a potential vaccine AZD1222, formerly kwn as ChOx1 nCoV-19. Oxford University recently anunced start of Phase II/III trial of AZD1222 in about 10,000 ult volunteers. new vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold (evirus) virus that causes infections in chimpanzees and contains genetic material of SARS-CoV-2 spike protein. After vaccination, surface spike protein is produced, priming immune system to attack COVID-19 if it later infects body.

Re: AstraZeneca, Oxford University Team Up To Develop COVID-19 Vaccine

Re: AstraZeneca Aims To Boost Potential Supply Of COVID-19 Vaccine To 2 Billion